UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Bapineuzumab Misses on ApoE4 Carriers
Go back to UBS Maintains a 'Buy' on Johnson & Johnson (JNJ); Bapineuzumab Misses on ApoE4 Carriers| Elan Corp. PLC ADS (NYSE: ELN) | Delayed: 18.12 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.12 | 52 Week High | $18.21 | |||
| Open | $18.12 | 52 Week Low | $9.37 | |||
| Day High | $18.12 | P/E | N/A | |||
| Day Low | $18.12 | EPS | $0.00 | |||
| Volume | 100 | |||||
| Johnson & Johnson (NYSE: JNJ) | Delayed: 260.35 -1.73 (0.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $262.08 | 52 Week High | $126.07 | |||
| Open | $260.65 | 52 Week Low | $94.28 | |||
| Day High | $261.71 | P/E | 54.13 | |||
| Day Low | $259.16 | EPS | $4.81 | |||
| Volume | 4,998,268 | |||||
